Ketamine-assisted psychotherapy

Last updated

Ketamine-assisted psychotherapy is the use of prescribed doses of ketamine, an analgesic anesthetic with dissociative properties, in combination with psychotherapy for treatment of various psychiatric conditions. [1] [2] Ketamine-assisted psychotherapy shows potential in treating mental disorders including major depressive disorder, anxiety, obsessive–compulsive disorder, post-traumatic stress disorders, substance use disorder, and neuropathic pain. [2] [3] Despite initial usage as a rapid-acting antidepressant, its psychedelic effects have sparked interest in its potential for treatment of mental illnesses beyond depressive symptoms. [4] Ketamine's neuroplasticity-promoting effects appear to strengthen the cognitive restructuring that takes place through traditional psychotherapy, thereby leading to long-lasting behavioral change. [5] [6] Ketamine appears to offer promising results as an effective modality of treatment for a variety of mental conditions and was approved by the Food and Drug Administration (FDA) in the United States for usage in treatment-resistant depression, but does display areas in need of further research across different domains of mental illness. [7]

Contents

Background

Ketamine is a short-acting, noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that was discovered by Parke-Davis Labs and Dr. Calvin Lee Stevens in 1962 during research into derivatives of phencyclidine (PCP). [2] [8] It was first used clinically as a veterinary anesthetic that was first given to a human in 1964 as a potential replacement for PCP. Soon after, Parke-Davis filed a patent for the utilization of the anesthetic. [9] [10] With this patent, ketamine began to be used on the battlefield where it was considered the "buddy drug" because soldiers were able to administer it to one another. [11] Given its hallucinogenic properties, interest rapidly rose in the possibility of broader avenues of application, including within the field of psychiatry as a treatment for depression, substance use dependence, and more. [12] Thus, soon after discovery, ketamine has been used as an off-label medication for a diverse group of psychiatric symptoms across Europe and the United States, and a topic of robust investigation. [7] The US Food and Drug Administration (FDA) first approved the use of intranasal esketamine (Spravato)—an enantiomer of ketamine—for the use of ketamine-derived therapy for treatment-resistant depression, in 2019, [13] leading to the creation and expansion of telemedicine-based companies that practice ketamine-assisted psychotherapy, such as the Psychedelic Institute of Mental Health & Family Therapy. [14] Ketamine is currently one of three injected general anesthetics that the World Health Organisation includes in its Model List of Essential Medicines along with propofol and thiopental, and is listed as safe to use for children. [15]

Example of a ketamine vial being used for injection. Ketamine was initially used as a veterinary anesthetic. Ketmine Injection.jpg
Example of a ketamine vial being used for injection. Ketamine was initially used as a veterinary anesthetic.

Rationale for interest

As of 2023, the World Health Organization reported 230 million people worldwide as having depression, or around 3.8% of the human population. [16] The current therapy for depression includes, but is not limited to, psychotherapy, antidepressant medications, transcranial magnetic stimulation, electroconvulsive therapy, and lifestyle approaches. However, antidepressant treatment is heavily limited by its delayed onset of efficacy, with noticeable effects only appearing over a period of months. The Sequenced Treatment Alternatives to Relieve Depression Study (STAR*D) Trial [17] also found that patients had low response rates to alternative compounds after the failure of the first antidepressant. [2] [18] Thus, interest sparked for a more rapid treatment option that could also be used as an adjunct to previous therapies in treatment-resistant depression.

Research evidence has found that combining psychotherapy and antidepressant medications enhances the effects of both. [2] [12] [7] This combination of pharmacotherapy and psychotherapy has historically been efficacious in numerous instances, such as the pairing of psychotherapy with conventional antidepressants for mood and anxiety disorders, with naltrexone for alcohol and opioid dependence, and with bupropion for smoking cessation. [8] Ketamine offers a notable advantage as opposed to currently-approved antidepressants, as it has a rapid onset [19] (2–24 hours post-infusion) [20] of temporally limited, but sustained, antidepressant and analgesic effects (typically lasting 4–7 days). [2] Its dissociative, psychedelic effects could also provide patients with increased neuroplasticity and cognitive flexibility that would enable more effective participation in therapy sessions. [19] Therapy could, in turn, reinforce the effects and improvements facilitated by ketamine to provide longer-lasting treatment. [19] [21] Supplementing ketamine use with cognitive behaviour therapy (CBT), in particular, has the potential to help patients reverse their inaccurate beliefs and maladaptive processing of information, that lead to depressive mental states. [22]

Active mechanisms

Ketamine as an NMDA receptor antagonist Ketamine.svg
Ketamine as an NMDA receptor antagonist

There are several hypotheses as to the underlying neural and cognitive mechanisms responsible for the psychiatric effects of ketamine. [2] Its mechanism of action is as an NMDA receptor antagonist. As such, glutamate modulation is a well-known effect, which is specifically believed to confer increased synaptic excitability. Notably, however, the effects of ketamine are now believed to be larger in scope than previously thought, ultimately leading to greater synaptogenesis and neuroplasticity. [22] As demonstrated in animal models, the administration of ketamine propagates signaling pathways surmised to augment neuroplasticity. Key among these are mammalian target of rapamycin (mTOR), glycogen synthase kinase-3 (GSK3), and elongation factor 2 (eEF2) kinase. [2] Ketamine has also demonstrated its ability to increase brain-derived neurotrophic factor levels within the brain in animal studies, which ameliorates the effects of acute and chronic stress. [23] The subsequent increase in both synaptic excitation and neuroplasticity is believed to precipitate the powerful and immediate symptom reduction ketamine elicits for a variety of conditions. It has additionally been theorized that ketamine disrupts the reconsolidation of dysfunctional memories and, through doing so, diminishes the burden of those associated with trauma, anxiety, substance use, and so on. [24]

An individual speaking with a psychotherapist. A session with a psychotherapist (751707089).jpg
An individual speaking with a psychotherapist.

Clinical Uses

Treatment-resistant depression

The use of ketamine as an antidepressant has mainly been studied for the treatment of treatment-resistant depression(TRD). Single-dose use has been found to have noticeable and rapid anti-depressive effects that tend to last up to a week, accompanied by acute side-effects that resolve spontaneously. [25] It has also been shown to have a moderate-to-large effect in reducing suicidality in some patients suffering from suicidal ideation, [26] with visible efficacy within two hours of administration. This is in sharp contrast with currently-approved treatment options, whose delayed onset poses an increased risk for suicidality in patients. However, this potency cannot currently be generalised for non-depressed patients experiencing suicidal ideation.

Protocol and administration

Repeated sessions of ketamine-assisted psychotherapy have also been found to be an effective method for facilitating clinically-significant reduction in anxiety and depression, when conducted in private practice settings. Sessions may last up to three hours, with provisions for supervised recovery towards the end. [12] The time-to-relapse after ketamine treatment is typically 2–4 weeks, which is why a repeated dosage paradigm is used to increase its efficacy on treatment-resistant depression. Currently only 20% of the 2,500 ketamine clinics in the United States offer ketamine-assisted psychotherapy. [27]

The mode of ketamine administration is a crucial consideration in the use of ketamine-assisted psychotherapy for depression. It employs a dosage escalation strategy [12] to achieve different levels of dissociative effects, depending on the amount of alteration of consciousness needed for treatment. Lower-dose sublingual administration is recommended for sessions that require active therapist-patient communication, and higher-dose intramuscular administration takes place when an inward focus is needed, with eye coverings and music provided. [7] There is no notable difference in efficacy, however. [28] [7] Guidelines for the provision of psychotherapy are also variably defined, depending on the application, with it being delivered either simultaneously, or following the infusion of ketamine. [7]

Bipolar Disorder

Multiple studies have identified the beneficial effect of combining a mood-stabilizing agent with intravenous ketamine infusions for controlling the depressive phase of bipolar disorder. [29] Notably, depressive symptoms including suicidal ideations were improved rapidly within around 40 minutes, [30] [31] which is difficult with current antidepressant therapy. However, a few patients did experience dissociative and/or manic symptoms during therapy in multiple studies, and the long-term effects of ketamine therapy and alternative modes of ketamine administration (other than intravenous) remains unclear, prompting further research into the area before efficacy and safety can be determined. [29] [30] [31] Furthermore, research remains mixed on whether or not ketamine infusions are more effective than esketamine. [32]

Anxiety disorder

Studies on the effect of ketamine on anxiety disorders remains sparse in number. [32] However, limited studies have shown significantly improved symptoms of anxiety with ketamine, with various modalities of administration including intravenous, intramuscular, and oral. [32] [33] In these studies, ketamine appeared to be an effective method to lower anxiety rapidly, [32] but its long-term effects and combinations with other modes of therapy remain unclear. [34]

Obsessive-compulsive disorder

Ketamine appears to significantly improve symptoms of obsessive-compulsive disorders short-term, with improved effects when used in conjunction with cognitive behavioral therapy. [35] Of note, mild to moderate symptoms of obsessive thoughts and compulsions were treated with significant efficacy, even in patients with psychiatric comorbidities. [36]

Substance use disorder

Ketamine has been shown to significantly affect treatment rates and reduce cravings in multiple modalities of substance use disorder, including that of alcohol, cocaine, and opioids. [37] Ketamine therapy used in conjunction with psychotherapy also appeared to decrease cannabis use. [32] However, the mechanisms of action for these effects remain unknown, and the addictive effects of ketamine on patients prone to substance use disorder has not been studied. [32] [37]

Eating disorders

Eating disorders have been a challenge to treat due to varying degrees of effectiveness of current treatments and high rates of remission [38] , and is often a combination of psychotherapy with various psychotropic medications. [38] [39] Ketamine has been shown to be an effective treatment for eating disorders, particularly for anorexia nervosa. [39] [40] While ketamine's effects on treating eating disorders appear positive, especially in patients who have failed previous therapies, the limited number of clinical studies may indicate that more research must be done to demonstrate its efficacy and safety across the diverse modalities of eating disorders. [39]

Side effects

The most common side effects of both intravenous ketamine and intranasal esketamine include, but is not limited to: dissociation, disorientation, dizziness, nausea, and hypertension. [32] [41] [42] However, recent research has demonstrated a sublingual type of ketamine therapy that is both efficacious, able to be used from home, and low-risk. [43] Further research is needed to assess the long-term side effects of ketamine therapy in multiple modalities.

Legality

In the United States, ketamine is approved by the FDA as an anesthetic agent. [13] However, use of compounded ketamine for any psychiatric disorder is not approved by the FDA due to concerns for safety and efficacy, despite off-label prescriptions by healthcare professionals. [44] Since 2019, Only esketamine (Spravato) has been approved by the FDA since 2019 as a nasal spray for depression that is treatment-resistant or to control acute behaviors of suicidality. [44] Esketamine is under strict regulation and guidance from FDA and the Risk Evaluation and Mitigation Strategy (REMS), requiring patient monitoring after administration for safety. [13] Despite FDA's lack of approval, ketamine has been prescribed off-label by healthcare professionals to patients with a variety of psychiatric conditions, particularly in settings of treatment-resistant conditions. [45] [46] Potential risks associated with it include dissociation, sedation and abuse. Esketamine cannot be distributed outside of certified clinical settings. [13]

Limitations and future directions

Ketamine-assisted psychotherapy has the potential to show significant efficacy in the treatment of treatment-resistant depression and suicidality, among other mental disorders. But, extensive further research is needed for its effects and mechanisms of action to be properly understood. Currently, the lack of large, replicated clinical trials prevent existing results from being generalisable to the larger population. The current model of ketamine-assisted psychotherapy also uses repeated administration of ketamine, the long-term side effects of which are not fully known yet. High doses of ketamine could also have potentially toxic effects in patients. [47] Given that existing studies only have short-term follow-up, the long-term safety of patients who undergo repeated dosing is, therefore, unknown. Future trials should be of larger scale, with repeated ketamine dosing, regular monitoring and follow-up. They should also focus on integrating ketamine with other forms of therapy, including, but not limited to motivational enhancement therapy (MET) [2] and functional analytic psychotherapy (FAP). [2]

References

  1. ↑ Sachdeva, Bhuvi; Sachdeva, Punya; Ghosh, Shampa; Ahmad, Faizan; Sinha, Jitendra Kumar (2023). "Ketamine as a therapeutic agent in major depressive disorder and posttraumatic stress disorder: Potential medicinal and deleterious effects". Ibrain. 9 (1): 90–101. doi:10.1002/ibra.12094. ISSN   2769-2795. PMC   10528797 . PMID   37786516.
  2. 1 2 3 4 5 6 7 8 9 10 Drozdz, Sandra J; Goel, Akash; McGarr, Matthew W; Katz, Joel; Ritvo, Paul; Mattina, Gabriella F; Bhat, Venkat; Diep, Calvin; Ladha, Karim S (2022-12-31). "Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature". Journal of Pain Research. 15: 1691–1706. doi: 10.2147/JPR.S360733 . PMC   9207256 . PMID   35734507.
  3. ↑ Kew, Bess M.; Porter, Richard J.; Douglas, Katie M.; Glue, Paul; Mentzel, Charlotte L.; Beaglehole, Ben (2023-05-02). "Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review". BJPsych Open. 9 (3): e79. doi:10.1192/bjo.2023.53. ISSN   2056-4724. PMC   10228275 . PMID   37128856.
  4. ↑ Dahan, Jack D. C.; Dadiomov, David; Bostoen, Tijmen; Dahan, Albert (2024-10-06). "Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome". npj Mental Health Research. 3 (1): 45. doi:10.1038/s44184-024-00091-w. ISSN   2731-4251. PMC   11455954 . PMID   39369173.
  5. ↑ Krystal, John H. (2007-10-15). "Neuroplasticity as a Target for the Pharmacotherapy of Psychiatric Disorders: New Opportunities for Synergy with Psychotherapy". Biological Psychiatry. 62 (8): 833–834. doi:10.1016/j.biopsych.2007.08.017. ISSN   0006-3223. PMID   17916459. S2CID   41034050.
  6. ↑ Greenway, Kyle T.; Garel, Nicolas; Jerome, Lisa; Feduccia, Allison A. (2020-06-02). "Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments". Expert Review of Clinical Pharmacology. 13 (6): 655–670. doi:10.1080/17512433.2020.1772054. ISSN   1751-2433. PMID   32478631. S2CID   219169886.
  7. 1 2 3 4 5 6 Walsh, Zach; Mollaahmetoglu, Ozden Merve; Rootman, Joseph; Golsof, Shannon; Keeler, Johanna; Marsh, Beth; Nutt, David J.; Morgan, Celia J. A. (January 2022). "Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review". BJPsych Open. 8 (1): e19. doi:10.1192/bjo.2021.1061. ISSN   2056-4724. PMC   8715255 . PMID   35048815.
  8. 1 2 Mathai, David S.; Mora, Victoria; Garcia-Romeu, Albert (2022). "Toward Synergies of Ketamine and Psychotherapy". Frontiers in Psychology. 13: 868103. doi: 10.3389/fpsyg.2022.868103 . ISSN   1664-1078. PMC   8992793 . PMID   35401323.
  9. ↑ "History of Ketamine". TD Consultancy. Retrieved 2023-12-05.
  10. ↑ Le Daré, B.; Pelletier, R.; Morel, I.; Gicquel, T. (January 2022). "[History of Ketamine: An ancient molecule that is still popular today]". Annales Pharmaceutiques Françaises. 80 (1): 1–8. doi: 10.1016/j.pharma.2021.04.005 . ISSN   0003-4509. PMID   33915159.
  11. ↑ Mercer, S. J. (2009). "'The Drug of War'--a historical review of the use of Ketamine in military conflicts". Journal of the Royal Naval Medical Service. 95 (3): 145–150. doi:10.1136/jrnms-95-145. ISSN   0035-9033. PMID   20180434.
  12. 1 2 3 4 Dore, Jennifer; Turnipseed, Brent; Dwyer, Shannon; Turnipseed, Andrea; Andries, Julane; Ascani, German; Monnette, Celeste; Huidekoper, Angela; Strauss, Nicole; Wolfson, Phil (2019-03-15). "Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy". Journal of Psychoactive Drugs. 51 (2): 189–198. doi: 10.1080/02791072.2019.1587556 . ISSN   0279-1072. PMID   30917760. S2CID   85543704.
  13. 1 2 3 4 Research, Center for Drug Evaluation and (2022-02-16). "FDA alerts health care professionals of potential risks associated with compounded ketamine nasal spray". FDA.
  14. ↑ DeMarco, Michael (11 May 2024). "Psychedelic Cognitive Behavioral Therapy: On Ketamine, Context and Competencies in "Assisted-Psychotherapy"". Psychedelic Institute of Mental Health & Family Therapy .
  15. ↑ "eEML - Electronic Essential Medicines List". list.essentialmeds.org. Retrieved 2025-03-12.
  16. ↑ "Depressive disorder (depression)". www.who.int. Retrieved 2025-03-12.
  17. ↑ Sinyor, Mark; Schaffer, Ayal; Levitt, Anthony (March 2010). "The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: A Review". The Canadian Journal of Psychiatry. 55 (3): 126–135. doi:10.1177/070674371005500303. ISSN   0706-7437. PMID   20370962. S2CID   19442084.
  18. ↑ Naughton, Marie; Clarke, Gerard; O′Leary, Olivia F.; Cryan, John F.; Dinan, Timothy G. (2014-03-01). "A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action". Journal of Affective Disorders. 156: 24–35. doi:10.1016/j.jad.2013.11.014. ISSN   0165-0327. PMID   24388038.
  19. 1 2 3 Hasler, Gregor (June 2020). "Toward specific ways to combine ketamine and psychotherapy in treating depression". CNS Spectrums. 25 (3): 445–447. doi: 10.1017/S1092852919001007 . ISSN   1092-8529. PMID   31213212. S2CID   195067658.
  20. ↑ Singh, Jaskaran B.; Fedgchin, Maggie; Daly, Ella J.; De Boer, Peter; Cooper, Kimberly; Lim, Pilar; Pinter, Christine; Murrough, James W.; Sanacora, Gerard; Shelton, Richard C.; Kurian, Benji; Winokur, Andrew; Fava, Maurizio; Manji, Husseini; Drevets, Wayne C. (August 2016). "A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression". American Journal of Psychiatry. 173 (8): 816–826. doi: 10.1176/appi.ajp.2016.16010037 . ISSN   0002-953X. PMID   27056608.
  21. ↑ Doblin, Richard E.; Christiansen, Merete; Jerome, Lisa; Burge, Brad (2019-03-15). "The Past and Future of Psychedelic Science: An Introduction to This Issue". Journal of Psychoactive Drugs. 51 (2): 93–97. doi: 10.1080/02791072.2019.1606472 . ISSN   0279-1072. PMID   31132970. S2CID   167220251.
  22. 1 2 Joneborg, Isak; Lee, Yena; Di Vincenzo, Joshua D.; Ceban, Felicia; Meshkat, Shakila; Lui, Leanna M. W.; Fancy, Farhan; Rosenblat, Joshua D.; McIntyre, Roger S. (2022-10-15). "Active mechanisms of ketamine-assisted psychotherapy: A systematic review". Journal of Affective Disorders. 315: 105–112. doi:10.1016/j.jad.2022.07.030. ISSN   0165-0327. PMID   35905796. S2CID   251141313.
  23. ↑ Du, Rui; Han, Ruili; Niu, Kun; Xu, Jiaqiao; Zhao, Zihou; Lu, Guofang; Shang, Yulong (2022). "The Multivariate Effect of Ketamine on PTSD: Systematic Review and Meta-Analysis". Frontiers in Psychiatry. 13: 813103. doi: 10.3389/fpsyt.2022.813103 . ISSN   1664-0640. PMC   8959757 . PMID   35356723.
  24. ↑ Stein, Murray B.; Simon, Naomi M. (2021-02-01). "Ketamine for PTSD: Well, Isn't That Special". American Journal of Psychiatry. 178 (2): 116–118. doi:10.1176/appi.ajp.2020.20121677. ISSN   0002-953X. PMID   33517752. S2CID   231752701.
  25. ↑ Corriger, Alexandrine; Pickering, Gisèle (2019-12-31). "Ketamine and depression: a narrative review". Drug Design, Development and Therapy. 13: 3051–3067. doi: 10.2147/DDDT.S221437 . PMC   6717708 . PMID   31695324.
  26. ↑ Nowacka, Agata; Borczyk, Malgorzata (2019-10-05). "Ketamine applications beyond anesthesia – A literature review". European Journal of Pharmacology. 860: 172547. doi:10.1016/j.ejphar.2019.172547. ISSN   0014-2999. PMID   31348905. S2CID   198934018.
  27. ↑ "About Healing Maps".
  28. ↑ Andrade, Chittaranjan (2017-08-23). "Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency?". The Journal of Clinical Psychiatry. 78 (7): e852 –e857. doi: 10.4088/JCP.17f11738 . ISSN   0160-6689. PMID   28749092.
  29. 1 2 Bahji, Anees; Zarate, Carlos A.; Vazquez, Gustavo H. (2021-07-23). "Ketamine for Bipolar Depression: A Systematic Review". The International Journal of Neuropsychopharmacology. 24 (7): 535–541. doi:10.1093/ijnp/pyab023. ISSN   1469-5111. PMC   8299822 . PMID   33929489.
  30. 1 2 Zarate, Carlos A.; Brutsche, Nancy E.; Ibrahim, Lobna; Franco-Chaves, Jose; Diazgranados, Nancy; Cravchik, Anibal; Selter, Jessica; Marquardt, Craig A.; Liberty, Victoria; Luckenbaugh, David A. (2012-06-01). "Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial". Biological Psychiatry. 71 (11): 939–946. doi:10.1016/j.biopsych.2011.12.010. ISSN   1873-2402. PMC   3343177 . PMID   22297150.
  31. 1 2 Diazgranados, Nancy; Ibrahim, Lobna; Brutsche, Nancy E.; Newberg, Andrew; Kronstein, Phillip; Khalife, Sami; Kammerer, William A.; Quezado, Zenaide; Luckenbaugh, David A.; Salvadore, Giacomo; Machado-Vieira, Rodrigo; Manji, Husseini K.; Zarate, Carlos A. (August 2010). "A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression". Archives of General Psychiatry. 67 (8): 793–802. doi:10.1001/archgenpsychiatry.2010.90. ISSN   1538-3636. PMC   3000408 . PMID   20679587.
  32. 1 2 3 4 5 6 7 Johnston, Jenessa N.; Kadriu, Bashkim; Kraus, Christoph; Henter, Ioline D.; Zarate, Carlos A. (January 2024). "Ketamine in neuropsychiatric disorders: an update". Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology. 49 (1): 23–40. doi:10.1038/s41386-023-01632-1. ISSN   1740-634X. PMC   10700638 . PMID   37340091.
  33. ↑ Whittaker, Elizabeth; Dadabayev, Alisher R.; Joshi, Sonalee A.; Glue, Paul (2021). "Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders". Therapeutic Advances in Psychopharmacology. 11: 20451253211056743. doi:10.1177/20451253211056743. ISSN   2045-1253. PMC   8679040 . PMID   34925757.
  34. ↑ Tully, Jamie L.; Dahlén, Amelia D.; Haggarty, Connor J.; Schiöth, Helgi B.; Brooks, Samantha (October 2022). "Ketamine treatment for refractory anxiety: A systematic review". British Journal of Clinical Pharmacology. 88 (10): 4412–4426. doi:10.1111/bcp.15374. ISSN   1365-2125. PMC   9540337 . PMID   35510346.
  35. ↑ Martinotti, Giovanni; Chiappini, Stefania; Pettorruso, Mauro; Mosca, Alessio; Miuli, Andrea; Di Carlo, Francesco; D'Andrea, Giacomo; Collevecchio, Roberta; Di Muzio, Ilenia; Sensi, Stefano L.; Di Giannantonio, Massimo (2021-06-27). "Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature". Brain Sciences. 11 (7): 856. doi: 10.3390/brainsci11070856 . ISSN   2076-3425. PMC   8301752 . PMID   34199023.
  36. ↑ Ferguson, Asila A.; Khan, Aujala Irfan; Abuzainah, Baraa; Chaudhuri, Dipabali; Khan, Kokab Irfan; Al Shouli, Roba; Allakky, Akhil; Hamdan, Jaafar A. (April 2023). "Clinical Effectiveness of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Adult Obsessive-Compulsive Disorder (OCD) Treatment: A Systematic Review". Cureus. 15 (4): e37833. doi: 10.7759/cureus.37833 . ISSN   2168-8184. PMC   10198239 . PMID   37213965.
  37. 1 2 Famuła, Anna; Radoszewski, Jakub; Czerwiec, Tomasz; Sobiś, Jarosław; Więckiewicz, Gniewko (March 2024). "Ketamine in Substance Use Disorder Treatment: A Narrative Review". Alpha Psychiatry. 25 (2): 206–211. doi:10.5152/alphapsychiatry.2024.241522. ISSN   2757-8038. PMC   11117434 . PMID   38798813.
  38. 1 2 Monteleone, Alessio Maria; Pellegrino, Francesca; Croatto, Giovanni; Carfagno, Marco; Hilbert, Anja; Treasure, Janet; Wade, Tracey; Bulik, Cynthia M.; Zipfel, Stephan; Hay, Phillipa; Schmidt, Ulrike; Castellini, Giovanni; Favaro, Angela; Fernandez-Aranda, Fernando; Il Shin, Jae (November 2022). "Treatment of eating disorders: A systematic meta-review of meta-analyses and network meta-analyses". Neuroscience and Biobehavioral Reviews. 142: 104857. doi:10.1016/j.neubiorev.2022.104857. ISSN   1873-7528. PMC   9813802 . PMID   36084848.
  39. 1 2 3 Ragnhildstveit, Anya; Slayton, Matthew; Jackson, Laura Kate; Brendle, Madeline; Ahuja, Sachin; Holle, Willis; Moore, Claire; Sollars, Kellie; Seli, Paul; Robison, Reid (2022-03-12). "Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions". Brain Sciences. 12 (3): 382. doi: 10.3390/brainsci12030382 . ISSN   2076-3425. PMC   8963252 . PMID   35326338.
  40. ↑ Calder, Abigail; Mock, Seline; Friedli, Nicole; Pasi, Patrick; Hasler, Gregor (October 2023). "Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms". European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology. 75: 1–14. doi:10.1016/j.euroneuro.2023.05.008. ISSN   1873-7862. PMID   37352816.
  41. ↑ "SPRAVATO® (esketamine) | Official Patient Website". SPRAVATO® (esketamine) | Official Patient Website. Retrieved 2025-03-15.
  42. ↑ "Ketamine". DEA. Archived from the original on 2025-03-13. Retrieved 2025-03-15.
  43. ↑ Hull, Thomas D.; Malgaroli, Matteo; Gazzaley, Adam; Akiki, Teddy J.; Madan, Alok; Vando, Leonardo; Arden, Kristin; Swain, Jack; Klotz, Madeline; Paleos, Casey (2022-10-01). "At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial". Journal of Affective Disorders. 314: 59–67. doi: 10.1016/j.jad.2022.07.004 . ISSN   1573-2517. PMID   35809678.
  44. 1 2 "FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders". FDA. 10 October 2023.
  45. ↑ "What to Know About Ketamine | Johns Hopkins | Bloomberg School of Public Health". publichealth.jhu.edu. 2024-01-26. Retrieved 2025-03-13.
  46. ↑ Wilkinson, Samuel T.; Sanacora, Gerard (2017-09-05). "Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders". JAMA. 318 (9): 793–794. doi:10.1001/jama.2017.10697. ISSN   1538-3598. PMC   6248331 . PMID   28806440.
  47. ↑ Short, Brooke; Fong, Joanna; Galvez, Veronica; Shelker, William; Loo, Colleen K (January 2018). "Side-effects associated with ketamine use in depression: a systematic review". The Lancet Psychiatry. 5 (1): 65–78. doi:10.1016/S2215-0366(17)30272-9. PMID   28757132.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.